Psoriatic Arthritis - Pipeline Review, H2 2016

 

Rating

4.7 Star Rating for report Psoriatic Arthritis - Pipeline Review, H2 2016
4.7 / 5 stars rating
Pages: 231
Price: $2000.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Pipeline Review, H2 2016, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8765IDBDermatomyositis - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8764IDBAxial Spondyloarthritis - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8738IDBPolyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Re...Nov 2016
Report... 05IB-GMDHC8714IDBPigmented Villonodular Synovitis - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8699IDBOsteonecrosis - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8672IDBGouty Arthritis (Gout) - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8655IDBMuscular Dystrophy - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8639IDBAnkylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, ...Nov 2016
Report... 05IB-GMDHC8613IDBInclusion Body Myositis (IBM) - Pipeline Review, H2 2016Oct 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-11-16 

Report: Psoriatic Arthritis - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Psoriatic Arthritis Overview 8
Therapeutics Development 9
Pipeline Products for Psoriatic Arthritis - Overview 9
Pipeline Products for Psoriatic Arthritis - Comparative Analysis 10
Psoriatic Arthritis - Therapeutics under Development by Companies 11
Psoriatic Arthritis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Psoriatic Arthritis - Products under Development by Companies 18
Psoriatic Arthritis - Companies Involved in Therapeutics Development 22
3SBio Inc. 22
AbbVie Inc 23
AbGenomics International, Inc. 24
Alteogen Inc. 25
Amgen Inc. 26
Biocon Limited 27
Bionovis SA 28
Bristol-Myers Squibb Company 29
Celgene Corporation 30
Coherus BioSciences, Inc. 31
Eli Lilly and Company 32
Forward Pharma A/S 33
Genor BioPharma Co Ltd 34
Innovent Biologics, Inc. 35
Johnson & Johnson 36
Kadmon Corporation, LLC 37
KPI Therapeutics, Inc. 38
Momenta Pharmaceuticals, Inc. 39
Morphotek, Inc. 40
Mycenax Biotech Inc. 41
NeuClone Pty Ltd 42
Novo Nordisk A/S 43
Oncobiologics, Inc. 44
Pfizer Inc. 45
Prothena Corporation Plc 46
Reliance Life Sciences Pvt. Ltd. 47
Sandoz International GmbH 48
Therapeutic Proteins International, LLC 49
UCB SA 50
Valeant Pharmaceuticals International, Inc. 51
Vitae Pharmaceuticals, Inc. 52
Vitaeris Inc 53
Xbrane Biopharma AB 54
Psoriatic Arthritis - Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Target 56
Assessment by Mechanism of Action 59
Assessment by Route of Administration 62
Assessment by Molecule Type 64
Drug Profiles 66
abatacept - Drug Profile 66
AbGn-168H - Drug Profile 71
ABT-122 - Drug Profile 73
adalimumab biosimilar - Drug Profile 75
adalimumab biosimilar - Drug Profile 77
adalimumab biosimilar - Drug Profile 78
adalimumab biosimilar - Drug Profile 79
adalimumab biosimilar - Drug Profile 80
adalimumab biosimilar - Drug Profile 81
adalimumab biosimilar - Drug Profile 82
adalimumab biosimilar - Drug Profile 84
adalimumab biosimilar - Drug Profile 86
adalimumab biosimilar - Drug Profile 87
adalimumab biosimilar - Drug Profile 88
adalimumab biosimilar - Drug Profile 89
adalimumab biosimilar - Drug Profile 90
adalimumab biosimilar - Drug Profile 91
apremilast - Drug Profile 92
apremilast - Drug Profile 103
bimekizumab - Drug Profile 104
certolizumab pegol biosimilar - Drug Profile 106
clazakizumab - Drug Profile 107
dalazatide - Drug Profile 111
dimethyl fumarate - Drug Profile 116
DNX-114 - Drug Profile 118
DNX-514 - Drug Profile 119
Drug to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile 120
etanercept - Drug Profile 121
etanercept biosimilar - Drug Profile 123
etanercept biosimilar - Drug Profile 124
etanercept biosimilar - Drug Profile 125
etanercept biosimilar - Drug Profile 126
etanercept biosimilar - Drug Profile 127
etanercept biosimilar - Drug Profile 130
etanercept biosimilar - Drug Profile 131
golimumab - Drug Profile 133
golimumab biosimilar - Drug Profile 141
golimumab biosimilar - Drug Profile 142
guselkumab - Drug Profile 143
infliximab biosimilar - Drug Profile 147
infliximab biosimilar - Drug Profile 148
infliximab biosimilar - Drug Profile 149
infliximab biosimilar - Drug Profile 152
infliximab biosimilar - Drug Profile 153
infliximab biosimilar - Drug Profile 156
infliximab biosimilar - Drug Profile 157
INV-17 - Drug Profile 158
itolizumab - Drug Profile 159
ixekizumab - Drug Profile 161
KANAb-071 - Drug Profile 167
KD-025 - Drug Profile 168
liraglutide - Drug Profile 172
PRX-003 - Drug Profile 179
risankizumab - Drug Profile 181
tofacitinib citrate - Drug Profile 184
upadacitinib tartrate - Drug Profile 197
ustekinumab biosimilar - Drug Profile 199
ustekinumab biosimilar - Drug Profile 200
VALBRO-03 - Drug Profile 201
VTP-43742 - Drug Profile 202
Psoriatic Arthritis - Dormant Projects 205
Psoriatic Arthritis - Discontinued Products 207
Psoriatic Arthritis - Product Development Milestones 208
Featured News & Press Releases 208
Appendix 225
Methodology 225
Coverage 225
Secondary Research 225
Primary Research 225
Expert Panel Validation 225
Contact Us 225
Disclaimer 226
 

List of Tables

List of Tables
Number of Products under Development for Psoriatic Arthritis, H2 2016 14
Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 20
Comparative Analysis by Early Stage Development, H2 2016 21
Comparative Analysis by Unknown Stage Development, H2 2016 22
Products under Development by Companies, H2 2016 23
Products under Development by Companies, H2 2016 (Contd..1) 24
Products under Development by Companies, H2 2016 (Contd..2) 25
Products under Development by Companies, H2 2016 (Contd..3) 26
Psoriatic Arthritis - Pipeline by 3SBio Inc., H2 2016 27
Psoriatic Arthritis - Pipeline by AbbVie Inc, H2 2016 28
Psoriatic Arthritis - Pipeline by AbGenomics International, Inc., H2 2016 29
Psoriatic Arthritis - Pipeline by Alteogen Inc., H2 2016 30
Psoriatic Arthritis - Pipeline by Amgen Inc., H2 2016 31
Psoriatic Arthritis - Pipeline by Biocon Limited, H2 2016 32
Psoriatic Arthritis - Pipeline by Bionovis SA, H2 2016 33
Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H2 2016 34
Psoriatic Arthritis - Pipeline by Celgene Corporation, H2 2016 35
Psoriatic Arthritis - Pipeline by Coherus BioSciences, Inc., H2 2016 36
Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H2 2016 37
Psoriatic Arthritis - Pipeline by Forward Pharma A/S, H2 2016 38
Psoriatic Arthritis - Pipeline by Genor BioPharma Co Ltd, H2 2016 39
Psoriatic Arthritis - Pipeline by Innovent Biologics, Inc., H2 2016 40
Psoriatic Arthritis - Pipeline by Johnson & Johnson, H2 2016 41
Psoriatic Arthritis - Pipeline by Kadmon Corporation, LLC, H2 2016 42
Psoriatic Arthritis - Pipeline by KPI Therapeutics, Inc., H2 2016 43
Psoriatic Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 44
Psoriatic Arthritis - Pipeline by Morphotek, Inc., H2 2016 45
Psoriatic Arthritis - Pipeline by Mycenax Biotech Inc., H2 2016 46
Psoriatic Arthritis - Pipeline by NeuClone Pty Ltd, H2 2016 47
Psoriatic Arthritis - Pipeline by Novo Nordisk A/S, H2 2016 48
Psoriatic Arthritis - Pipeline by Oncobiologics, Inc., H2 2016 49
Psoriatic Arthritis - Pipeline by Pfizer Inc., H2 2016 50
Psoriatic Arthritis - Pipeline by Prothena Corporation Plc, H2 2016 51
Psoriatic Arthritis - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016 52
Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H2 2016 53
Psoriatic Arthritis - Pipeline by Therapeutic Proteins International, LLC, H2 2016 54
Psoriatic Arthritis - Pipeline by UCB SA, H2 2016 55
Psoriatic Arthritis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 56
Psoriatic Arthritis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016 57
Psoriatic Arthritis - Pipeline by Vitaeris Inc, H2 2016 58
Psoriatic Arthritis - Pipeline by Xbrane Biopharma AB, H2 2016 59
Assessment by Monotherapy Products, H2 2016 60
Number of Products by Stage and Target, H2 2016 62
Number of Products by Stage and Mechanism of Action, H2 2016 65
Number of Products by Stage and Route of Administration, H2 2016 68
Number of Products by Stage and Molecule Type, H2 2016 70
Psoriatic Arthritis - Dormant Projects, H2 2016 210
Psoriatic Arthritis - Dormant Projects (Contd..1), H2 2016 211
Psoriatic Arthritis - Discontinued Products, H2 2016 212
 

List of Figures

List of Figures
Number of Products under Development for Psoriatic Arthritis, H2 2016 14
Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 20
Comparative Analysis by Early Stage Products, H2 2016 21
Assessment by Monotherapy Products, H2 2016 60
Number of Products by Top 10 Targets, H2 2016 61
Number of Products by Stage and Top 10 Targets, H2 2016 61
Number of Products by Top 10 Mechanism of Actions, H2 2016 64
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 64
Number of Products by Routes of Administration, H2 2016 67
Number of Products by Stage and Routes of Administration, H2 2016 67
Number of Products by Molecule Types, H2 2016 69
Number of Products by Stage and Molecule Types, H2 2016 69
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 9, 8, 10, 2, 15, 7 and 2 respectively.Psoriatic Arthritis.

Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Musculoskeletal Disorders 
Pages: 231 

Companies Featured

3SBio Inc. AbbVie Inc AbGenomics International, Inc. Alteogen Inc. Amgen Inc. Biocon Limited Bionovis SA Bristol-Myers Squibb Company Celgene Corporation Coherus BioSciences, Inc. Eli Lilly and Company Forward Pharma A/S Genor BioPharma Co Ltd Innovent Biologics, Inc. Johnson & Johnson Kadmon Corporation, LLC KPI Therapeutics, Inc. Momenta Pharmaceuticals, Inc. Morphotek, Inc. Mycenax Biotech Inc. NeuClone Pty Ltd Novo Nordisk A/S Oncobiologics, Inc. Pfizer Inc. Prothena Corporation Plc Reliance Life Sciences Pvt. Ltd. Sandoz International GmbH Therapeutic Proteins International, LLC UCB SA Valeant Pharmaceuticals International, Inc. Vitae Pharmaceuticals, Inc. Vitaeris Inc Xbrane Biopharma AB

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Psoriatic Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8765IDBDermatomyositis - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8764IDBAxial Spondyloarthritis - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8738IDBPolyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Re...Nov 2016
Report... 05IB-GMDHC8714IDBPigmented Villonodular Synovitis - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8699IDBOsteonecrosis - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8672IDBGouty Arthritis (Gout) - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8655IDBMuscular Dystrophy - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8639IDBAnkylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, ...Nov 2016
Report... 05IB-GMDHC8613IDBInclusion Body Myositis (IBM) - Pipeline Review, H2 2016Oct 2016

Psoriatic Arthritis - Pipeline Review, H2 2016

Report 05IB-GMDHC8680IDB has a rating of 94 percent
Figure of merit assessment for report 05IB-GMDHC8680IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7199

Taxonomy Location

The taxonomy on the left shows the ancestors of the Musculoskeletal Disorders node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Musculoskeletal Disorders

Musculoskeletal Disorders

 

Healthcare Disorders

Healthcare Disorders

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Psoriatic Arthritis - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8680IDB

 
Licence: Single User
Price: $2000.00
 
VAT: 0.0% 
Total: $2000.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [1.40701s]

--